Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Danshensu Enhances Cerebral Angiogenesis in Mice by Regulating the PI3K/Akt/Mtor/VEGF Signaling Axis

Author(s): Hongning Jia*, Xiaoyuan Qi, Huijun Wu and Jianping Wang

Volume 22, Issue 4, 2023

Published on: 17 June, 2022

Page: [607 - 613] Pages: 7

DOI: 10.2174/1871527321666220329144538

open access plus

Abstract

Background: Cerebral infraction seriously affects the life quality of patients. Danshensu has been reported to exhibit anti-inflammatory and vascular protective effects. However, the therapeutic function of Danshensu in cerebral vascular injury is still unclear.

Methods: Middle cerebral artery occlusion (MCAO) was used to construct the cerebral infraction model. Wound healing and tube formation assays were used to evaluate angiogenesis in vitro. Western blot assay was used to evaluate the activation of the PI3K/Akt/mTOR signaling pathway. The laser Doppler scanner was used to measure the regional cerebral blood flow (rCBF) in the area around the infarction, and the adhesion removal test was used to measure the sensorimotor function. The Modified Neurological Severity Score was performed to evaluate the cognitive functions of mice.

Results: Danshensu promoted the proliferation of bEnd.3 cells and angiogenesis in vitro. Danshensu upregulated the expression of VEGF through PI3K/Akt/mTOR signaling pathway in bEnd.3 cells. Danshensu improved rCBF restoration and attenuated the behavioral deficits in mice post-MCAO/R.

Conclusion: Danshensu enhances angiogenesis through the PI3K/Akt/mTOR/VEGF signaling pathway in a mouse model of cerebral ischemic injury.

Keywords: Cerebral infraction, VEGF, Danshensu, angiogenesis, MCAO, thrombiolytic therapy.

« Previous Next »
[1]
Guzik A, Bushnell C. Stroke epidemiology and risk factor management. Continuum (Minneap Minn) 2017; 23(1, Cerebrovascular Disease): 15-39.
[http://dx.doi.org/10.1212/CON.0000000000000416] [PMID: 28157742]
[2]
Ye J, Sun Z, Hu W. Roles of astrocytes in cerebral infarction and related therapeutic strategies. Zhejiang Da Xue Xue Bao Yi Xue Ban 2018; 47(5): 493-8.
[PMID: 30693691]
[3]
Sun W, Li G, Zeng X, et al. Clinical and imaging characteristics of cerebral infarction in patients with nonvalvular atrial fibrillation combined with cerebral artery stenosis. J Atheroscler Thromb 2018; 25(8): 720-32.
[http://dx.doi.org/10.5551/jat.43240] [PMID: 29877196]
[4]
Jiang Q, Xiao S, Shu L, Huang X, Chen X, Hong H. Pituitary apoplexy leading to cerebral infarction: A systematic review. Eur Neurol 2020; 83(2): 121-30.
[http://dx.doi.org/10.1159/000507190] [PMID: 32544913]
[5]
Merkler AE, Alakbarli J, Barbar T, et al. Associations between the size and location of myocardial infarction and cerebral infarction. J Neurol Sci 2020; 419: 117182.
[http://dx.doi.org/10.1016/j.jns.2020.117182] [PMID: 33099172]
[6]
Marti C, John G, Konstantinides S, et al. Systemic thrombolytic therapy for acute pulmonary embolism: A systematic review and meta-analysis. Eur Heart J 2015; 36(10): 605-14.
[http://dx.doi.org/10.1093/eurheartj/ehu218] [PMID: 24917641]
[7]
Igneri LA, Hammer JM. Systemic thrombolytic therapy for massive and submassive pulmonary embolism. J Pharm Pract 2020; 33(1): 74-89.
[http://dx.doi.org/10.1177/0897190018767769] [PMID: 29673293]
[8]
Barletta JF. Streptokinase and urokinase for the treatment of pleural effusions and empyemas. Ann Pharmacother 1999; 33(4): 495-8.
[http://dx.doi.org/10.1345/aph.18219] [PMID: 10332542]
[9]
Dubé M, Soulez G, Thérasse E, et al. Comparison of streptokinase and urokinase in local thrombolysis of peripheral arterial occlusions for lower limb salvage. J Vasc Interv Radiol 1996; 7(4): 587-93.
[http://dx.doi.org/10.1016/S1051-0443(96)70810-2] [PMID: 8855542]
[10]
Nicholl SM, Roztocil E, Davies MG. Plasminogen activator system and vascular disease. Curr Vasc Pharmacol 2006; 4(2): 101-16.
[http://dx.doi.org/10.2174/157016106776359880] [PMID: 16611153]
[11]
Rowaiye OO, Kusztal M, Zabinska M, et al. Anti-ETAR and suPAR as markers of disease activity in renal ANCA-associated vasculitis. Adv Med Sci 2021; 67(1): 23-8.
[http://dx.doi.org/10.1016/j.advms.2021.11.002] [PMID: 34781174]
[12]
Seillier C, Hélie P, Petit G, et al. Roles of the tissue-type plasminogen activator in immune response. Cell Immunol 2022; 371: 104451.
[http://dx.doi.org/10.1016/j.cellimm.2021.104451] [PMID: 34781155]
[13]
Jia S, Chen Q, Wu J, et al. Danshensu derivative ADTM ameliorates CCl4-induced acute liver injury in mice through inhibiting oxidative stress and apoptosis. Pathol Res Pract 2021; 228: 153656.
[http://dx.doi.org/10.1016/j.prp.2021.153656] [PMID: 34749210]
[14]
Lataliza AAB, de Assis PM, da Rocha Laurindo L, Gonçalves ECD, Raposo NRB, Dutra RC. Antidepressant-like effect of rosmarinic acid during LPS-induced neuroinflammatory model: The potential role of cannabinoid receptors/PPAR-γ signaling pathway. Phytother Res 2021; 35(12): 6974-89.
[http://dx.doi.org/10.1002/ptr.7318] [PMID: 34709695]
[15]
Huang Q, Qi J, Gao Z, et al. Chemical composition and protective effect of cerebrospinal fluid of Dan-deng-tong-nao capsules on brain microvascular endothelial cells injured by OGD/R. J Ethnopharmacol 2022; 283: 114705.
[http://dx.doi.org/10.1016/j.jep.2021.114705] [PMID: 34655669]
[16]
Chiang T, Messing RO, Chou WH. Mouse model of middle cerebral artery occlusion. J Vis Exp 2011; (48): 2761.
[http://dx.doi.org/10.3791/2761] [PMID: 21372780]
[17]
Teng H, Chopp M, Hozeska-Solgot A, et al. Tissue plasminogen activator and plasminogen activator inhibitor 1 contribute to sonic hedgehog-induced in vitro cerebral angiogenesis. PLoS One 2012; 7(3): e33444.
[http://dx.doi.org/10.1371/journal.pone.0033444] [PMID: 22432023]
[18]
Fei Y, Zhao B, Zhu J, Fang W, Li Y. XQ-1H promotes cerebral angiogenesis via activating PI3K/Akt/GSK3β/β-catenin/VEGF signal in mice exposed to cerebral ischemic injury. Life Sci 2021; 272: 119234.
[http://dx.doi.org/10.1016/j.lfs.2021.119234] [PMID: 33607158]
[19]
Kim JS, Kim YJ, Ahn SH, Kim BJ. Location of cerebral atherosclerosis: Why is there a difference between East and West? Int J Stroke 2018; 13(1): 35-46.
[http://dx.doi.org/10.1177/1747493016647736] [PMID: 27145795]
[20]
Qureshi AI, Caplan LR. Intracranial atherosclerosis. Lancet 2014; 383(9921): 984-98.
[http://dx.doi.org/10.1016/S0140-6736(13)61088-0] [PMID: 24007975]
[21]
Zhang S, Wang N, Chen L, et al. Serum aldosterone is associated with cerebral artery atherosclerosis and calcification. J Stroke Cerebrovasc Dis 2019; 28(3): 523-30.
[http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2018.09.053] [PMID: 30528672]
[22]
Lee EJ, Chung CH, Choi KH, et al. The impact of cerebral atherosclerosis according to location on prognosis after coronary artery bypass grafting. Cerebrovasc Dis 2018; 46(5-6): 200-9.
[http://dx.doi.org/10.1159/000494502] [PMID: 30408800]
[23]
Gao J, Yang S, Wang K, Zhong Q, Ma A, Pan X. Plasma miR-126 and miR-143 as Potential novel biomarkers for cerebral atherosclerosis. J Stroke Cerebrovasc Dis 2019; 28(1): 38-43.
[http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2018.09.008] [PMID: 30309729]
[24]
Zhang S, Song G, Yuan J, et al. Circular RNA circ_0003204 inhibits proliferation, migration and tube formation of endothelial cell in atherosclerosis via miR-370-3p/TGFβR2/phosph-SMAD3 axis. J Biomed Sci 2020; 27(1): 11.
[http://dx.doi.org/10.1186/s12929-019-0595-9] [PMID: 31900142]
[25]
Jain T, Nikolopoulou EA, Xu Q, Qu A. Hypoxia inducible factor as a therapeutic target for atherosclerosis. Pharmacol Ther 2018; 183: 22-33.
[http://dx.doi.org/10.1016/j.pharmthera.2017.09.003] [PMID: 28942242]
[26]
Chapple SJ, Cheng X, Mann GE. Effects of 4-hydroxynonenal on vascular endothelial and smooth muscle cell redox signaling and function in health and disease. Redox Biol 2013; 1(1): 319-31.
[http://dx.doi.org/10.1016/j.redox.2013.04.001] [PMID: 24024167]
[27]
Wang T, Li C, Han B, et al. Neuroprotective effects of danshensu on rotenone-induced Parkinson’s disease models in vitro and in vivo. BMC Complement Med Ther 2020; 20(1): 20.
[http://dx.doi.org/10.1186/s12906-019-2738-7] [PMID: 32020857]
[28]
Zhang J, Zhang Q, Liu G, Zhang N. Therapeutic potentials and mechanisms of the Chinese traditional medicine Danshensu. Eur J Pharmacol 2019; 864: 172710.
[http://dx.doi.org/10.1016/j.ejphar.2019.172710] [PMID: 31586468]
[29]
Sun DW, Gao Q, Qi X. Danshensu ameliorates cardiac ischaemia reperfusion injury through activating sirt1/foxo1/rab7 signal pathway. Chin J Integr Med 2020; 26(4): 283-91.
[http://dx.doi.org/10.1007/s11655-019-3165-9] [PMID: 31254156]
[30]
Han B, Che X, Zhao Y, et al. Neuroprotective effects of danshensu in Parkinson’s disease mouse model induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Behav Pharmacol 2019; 30(1): 36-44.
[http://dx.doi.org/10.1097/FBP.0000000000000412] [PMID: 29847337]
[31]
Bae HJ, Sowndhararajan K, Park HB, et al. Danshensu attenuates scopolamine and amyloid-β-induced cognitive impairments through the activation of PKA-CREB signaling in mice. Neurochem Int 2019; 131: 104537.
[http://dx.doi.org/10.1016/j.neuint.2019.104537] [PMID: 31425745]
[32]
Kumar VB, Lin SH, Mahalakshmi B, et al. Sodium danshensu inhibits oral cancer cell migration and invasion by modulating p38 signaling pathway. Front Endocrinol (Lausanne) 2020; 11: 568436.
[http://dx.doi.org/10.3389/fendo.2020.568436] [PMID: 33101201]
[33]
Liu G, Zhang Q, Zhang J, Zhang N. Preventive but nontherapeutic effect of danshensu on hypoxic pulmonary hypertension. J Int Med Res 2020; 48(5): 300060520914218.
[http://dx.doi.org/10.1177/0300060520914218] [PMID: 32419546]

Rights & Permissions Print Cite
Article Metrics
9
© 2024 Bentham Science Publishers | Privacy Policy